These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30451307)

  • 1. Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis.
    Tang Q; Ramsköld D; Krystufkova O; Mann HF; Wick C; Dastmalchi M; Lakshmikanth T; Chen Y; Mikes J; Alexanderson H; Achour A; Brodin P; Vencovsky J; Lundberg IE; Malmström V
    Scand J Immunol; 2019 Jan; 89(1):e12732. PubMed ID: 30451307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis.
    Pandya JM; Loell I; Hossain MS; Zong M; Alexanderson H; Raghavan S; Lundberg IE; Malmström V
    Arthritis Res Ther; 2016 Apr; 18():80. PubMed ID: 27039301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial.
    Tjärnlund A; Tang Q; Wick C; Dastmalchi M; Mann H; Tomasová Studýnková J; Chura R; Gullick NJ; Salerno R; Rönnelid J; Alexanderson H; Lindroos E; Aggarwal R; Gordon P; Vencovsky J; Lundberg IE
    Ann Rheum Dis; 2018 Jan; 77(1):55-62. PubMed ID: 28993346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients.
    Benveniste O; Chérin P; Maisonobe T; Merat R; Chosidow O; Mouthon L; Guillevin L; Flahault A; Burland MC; Klatzmann D; Herson S; Boyer O
    J Immunol; 2001 Sep; 167(6):3521-9. PubMed ID: 11544346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis.
    Wang DX; Lu X; Zu N; Lin B; Wang LY; Shu XM; Ma L; Wang GC
    Clin Rheumatol; 2012 Dec; 31(12):1691-7. PubMed ID: 22933126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor α expression in muscle tissue of patients with polymyositis or dermatomyositis.
    Zong M; Loell I; Lindroos E; Nader GA; Alexanderson H; Hallengren CS; Borg K; Arnardottir S; McInnes IB; Lundberg IE
    Ann Rheum Dis; 2012 Jun; 71(6):1055-63. PubMed ID: 22267334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis.
    Aleksza M; Szegedi A; Antal-Szalmás P; Irinyi B; Gergely L; Ponyi A; Hunyadi J; Sipka S; Zeher M; Szegedi G; Dankó K
    Ann Rheum Dis; 2005 Oct; 64(10):1485-9. PubMed ID: 15829578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute reduction of regulatory T cells and regulatory effect of short-term and low-dose IL-2 in polymyositis or dermatomyositis.
    Feng M; Guo H; Zhang C; Wang Y; Liang Z; Zhao X; Qin Y; Wu Y; Liu G; Gao C; Luo J
    Int Immunopharmacol; 2019 Dec; 77():105912. PubMed ID: 31669890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells.
    Fasth AE; Dastmalchi M; Rahbar A; Salomonsson S; Pandya JM; Lindroos E; Nennesmo I; Malmberg KJ; Söderberg-Nauclér C; Trollmo C; Lundberg IE; Malmström V
    J Immunol; 2009 Oct; 183(7):4792-9. PubMed ID: 19752224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.
    Higgs BW; Zhu W; Morehouse C; White WI; Brohawn P; Guo X; Rebelatto M; Le C; Amato A; Fiorentino D; Greenberg SA; Drappa J; Richman L; Greth W; Jallal B; Yao Y
    Ann Rheum Dis; 2014 Jan; 73(1):256-62. PubMed ID: 23434567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis.
    Baka Z; Senolt L; Vencovsky J; Mann H; Simon PS; Kittel A; Buzás E; Nagy G
    Immunol Lett; 2010 Feb; 128(2):124-30. PubMed ID: 20043950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-lymphocyte immunophenotyping in polymyositis and dermatomyositis.
    Iannone F; Cauli A; Yanni G; Kingsley GH; Isenberg DA; Corrigall V; Panayi GS
    Br J Rheumatol; 1996 Sep; 35(9):839-45. PubMed ID: 8810666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
    Adams EM; Pucino F; Yarboro C; Hicks JE; Thornton B; McGarvey C; Sonies BC; Bartlett ML; Villalba ML; Fleisher T; Plotz PH
    J Rheumatol; 1999 Feb; 26(2):352-60. PubMed ID: 9972969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell receptor-mediated characteristic signaling pathway of peripheral blood T cells in dermatomyositis and polymyositis.
    Shimojima Y; Matsuda M; Ishii W; Kishida D; Sekijima Y
    Autoimmunity; 2017 Dec; 50(8):481-490. PubMed ID: 29172719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment of polymyositis and dermatomyositis.
    Murthy JM
    Neurol India; 2010; 58(1):3-5. PubMed ID: 20228455
    [No Abstract]   [Full Text] [Related]  

  • 16. Polymyositis and dermatomyositis.
    Dalakas MC; Hohlfeld R
    Lancet; 2003 Sep; 362(9388):971-82. PubMed ID: 14511932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies.
    De Bleecker JL; Engel AG
    Am J Pathol; 1995 May; 146(5):1178-87. PubMed ID: 7747812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy.
    Venalis P; Lundberg IE
    Rheumatology (Oxford); 2014 Mar; 53(3):397-405. PubMed ID: 23970542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
    Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
    Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis.
    Lundberg I; Kratz AK; Alexanderson H; Patarroyo M
    Arthritis Rheum; 2000 Feb; 43(2):336-48. PubMed ID: 10693873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.